RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BOCCADORO M
Collezione ASL Vercelli

Items : 8

SUPPORTING TREATMENT DECISION-MAKING FOR LENALIDOMIDE- REFRACTORY MULTIPLE MYELOMA PATIENTS POSTDRD IN ITALY: A MULTI-CRITERIA DECISION FRAMEWORK in Haematologica

2025
ASL Vercelli

Boccadoro M; Belotti A; Bombaci F; Bringhen S; Buda G; Cafro AM; Caimmi M; Canali B; Canonico PL; Cavo M; Corso A; De Paoli L; Derudas D; Di Raimondo F; Galeone C; Gay F; Gentile M; Giuliani N; La Malfa P; Mercati R; Montefusco V; Musto P; Offidani M; Patriarca F; Petrucci MT; Riccaboni M; Tosi P; Zamagni E; Zambello R; et alii...

Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy in Annals of Hematology

2025
ASL Vercelli

Conticello C; Fabro VD; Romano A; Mele A; Mina R; Bringhen S; Orofino A; Antonioli E; Pulini S; De Paoli L; Za T; Cotzia E; Elia F; Casson A; Prete E; Citiso S; Liberatore C; Margiotta-Casaluci G; Fazio F; Morè S; Attucci I; Accardi F; Bongarzoni V; Mangiacavalli S; Rossi E; Mannina D; Garibaldi B; Rizzi R; Di Cecca M; et alii...

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. in Blood / Blood. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16.

2013
AOU Città della Salute di Torino
ASL Vercelli

Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A;

Salvage treatment with pomalidomide-cyclophosphamideprednisone produces similar outcomes as compared to prior therapies in patients with relapsed/refractory multiple myeloma in Haematologica

2013
ASL Vercelli

Larocca A; Montefusco V; Oliva S; Spriano M; Santagostino A; Genuardi M; Rota-Scalabrini D; Guglielmelli T; Giuliani N; Moscetti A; Mina R; Marcatti M; Galli M; Gilestro M; Crippa C; Baldi I; Rossi D; Boccadoro M; Corradini P; Palumbo A;

Pomalidomide cyclophosphamide and prednisone is active in lenalidomide relapsed/ refractory multiple myeloma in Clinical Lymphoma, Myeloma and Leukemia

2013
ASL Vercelli

Larocca A; Montefusco V; Oliva S; Rossi D; Crippa C; Genuardi M; Galli M; Marcatti M; Moscetti A; Giuliani N; Mina R; Guglielmelli T; Rota-Scalabrini D; Oddolo D; Santagostino A; Baldi I; Spriano M; Boccadoro M; Corradini P; Palumbo A;

Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma in Blood

2012
ASL Vercelli

Palumbo A; Larocca A; Montefusco V; Rossi D; Carella AM; Mina R; Crippa C; Sciacca M; Galli M; Scalabrini DR; Marcatti M; Guglielmelli T; Giuliani N; La Verde G; Baldi I; Muccio VE; Boccadoro M; Corradini P;

High response rates to pomalidomide-cyclophosphamideprednisone (PCP) in patients with multiple myeloma relapsed/refractory to lenalidomide: Results of a phase I/II study in Haematologica

2012
ASL Vercelli

Palumbo A; Larocca A; Lupo B; Montefusco V; Rossi D; Carella A; Crippa C; Santagostino A; Galli M; Rota Scalabrini D; Marcatti M; Guglielmelli T; Giuliani N; Laverde G; Magarotto V; Saraci E; Baldi I; Boccadoro M; Corradini P;

A phase I/II study of pomalidomide-cyclophosphamide-prednisone (PCP) in patients with multiple myeloma relapsed/refractory to lenalidomide in Blood

2011
ASL Vercelli

Palumbo A; Larocca A; Carella AM; Rossi D; Montefusco V; Ferrari S; Santagostino A; Guglielmelli T; Galli M; Capaldi A; Giuliani N; Verde GL; Omedè P; Baldi I; Boccadoro M; Corradini P;